99 related articles for article (PubMed ID: 19596701)
1. Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case-control retrospective analysis.
Delgado J; Pillai S; Phillips N; Brunet S; Pratt G; Briones J; Lovell R; Martino R; Ewing J; Sureda A; Milligan DW; Sierra J
Ann Oncol; 2009 Dec; 20(12):2007-12. PubMed ID: 19596701
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens.
Kharfan-Dabaja MA; Bazarbachi A
Cancer Control; 2012 Jan; 19(1):68-75. PubMed ID: 22143063
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
[TBL] [Abstract][Full Text] [Related]
4. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia.
Hamadani M; Mohty M; Kharfan-Dabaja MA
Cancer Control; 2011 Oct; 18(4):237-45. PubMed ID: 21976242
[TBL] [Abstract][Full Text] [Related]
5. Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning.
Andersen NS; Bornhäuser M; Gramatzki M; Dreger P; Vitek A; Karas M; Michallet M; Moreno C; van Gelder M; Henseler A; de Wreede LC; Schönland S; Kröger N; Schetelig J;
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2823-2834. PubMed ID: 31468122
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic transplantation for high-risk chronic lymphocytic leukemia-a summary of a 16-year experience.
Helbig G; Spałek A; Wieczorkiewicz-Kabut A; Markiewicz M; Kopera M; Zielińska P; Woźniczka K; Kopińska A; Grygoruk-Wiśniowska I; Koclęga A
Ann Hematol; 2019 Jun; 98(6):1477-1483. PubMed ID: 30919074
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors to predict outcome of reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukemia.
Jindra P; Raida L; Lysak D; Karas M; Papajik T; Jungova A; Mohammadová L; Houdova L
Neoplasma; 2016; 63(4):595-600. PubMed ID: 27268923
[TBL] [Abstract][Full Text] [Related]
8. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.
Richardson SE; Khan I; Rawstron A; Sudak J; Edwards N; Verfuerth S; Fielding AK; Goldstone A; Kottaridis P; Morris E; Benjamin R; Peggs KS; Thomson KJ; Vandenberghe E; Mackinnon S; Chakraverty R
Br J Haematol; 2013 Mar; 160(5):640-8. PubMed ID: 23293871
[TBL] [Abstract][Full Text] [Related]
9. CD34
Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
[TBL] [Abstract][Full Text] [Related]
10. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.
Chhabra S; Ahn KW; Hu ZH; Jain S; Assal A; Cerny J; Copelan EA; Daly A; DeFilipp Z; Gadalla SM; Gale RP; Ganguly S; Hamilton BK; Hildebrandt GC; Hsu JW; Inamoto Y; Kanate AS; Khoury HJ; Lazarus HM; Litzow MR; Nathan S; Olsson RF; Pawarode A; Ringden O; Rowe JM; Saad A; Savani BN; Schouten HC; Seo S; Shah NN; Solh M; Stuart RK; Ustun C; Woolfrey AE; Yared JA; Alyea EP; Kalaycio ME; Popat U; Sobecks RM; Saber W
Blood Adv; 2018 Nov; 2(21):2922-2936. PubMed ID: 30396912
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
12. Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis.
Kharfan-Dabaja MA; Pidala J; Kumar A; Terasawa T; Djulbegovic B
Bone Marrow Transplant; 2012 Sep; 47(9):1164-70. PubMed ID: 22562081
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
[TBL] [Abstract][Full Text] [Related]
14. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.
Kharfan-Dabaja MA; Kumar A; Hamadani M; Stilgenbauer S; Ghia P; Anasetti C; Dreger P; Montserrat E; Perales MA; Alyea EP; Awan FT; Ayala E; Barrientos JC; Brown JR; Castro JE; Furman RR; Gribben J; Hill BT; Mohty M; Moreno C; O'Brien S; Pavletic SZ; Pinilla-Ibarz J; Reddy NM; Sorror M; Bredeson C; Carpenter P; Savani BN
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2117-2125. PubMed ID: 27660167
[TBL] [Abstract][Full Text] [Related]
15. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
Brown JR; Kim HT; Li S; Stephans K; Fisher DC; Cutler C; Ho V; Lee SJ; Milford EL; Ritz J; Antin JH; Soiffer RJ; Gribben JG; Alyea EP
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1056-64. PubMed ID: 17084369
[TBL] [Abstract][Full Text] [Related]
16. Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics.
Yamasaki S; Yoshimoto G; Ogawa R; Aoki K; Higuchi M; Harada N; Arima F; Kondo S; Matubara F; Takahashi T; Uike N; Miyamoto T; Okamura S; Akashi K;
Ann Hematol; 2015 Jul; 94(7):1159-65. PubMed ID: 25704584
[TBL] [Abstract][Full Text] [Related]
17. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis.
Dreger P; Brand R; Milligan D; Corradini P; Finke J; Lambertenghi Deliliers G; Martino R; Russell N; van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2005 Jun; 19(6):1029-33. PubMed ID: 15830011
[TBL] [Abstract][Full Text] [Related]
18. The effect of allogeneic stem cell transplantation on high risk chronic lymphocytic leukaemia: a single centre retrospective analysis.
Válková V; Schwarz J; Vítek A; Marková M; Pohlreich D; Benešová K; Michalová K; Cetkovský P; Trněný M
Hematol Oncol; 2011 Mar; 29(1):22-30. PubMed ID: 20535783
[TBL] [Abstract][Full Text] [Related]
19. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
20. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
